Sarepta Therapeutics
SRPT
464 hedge funds and large institutions have $10.7B invested in Sarepta Therapeutics in 2024 Q4 according to their latest regulatory filings, with 78 funds opening new positions, 157 increasing their positions, 158 reducing their positions, and 64 closing their positions.
38% more funds holding in top 10
Funds holding in top 10: 8 → 11 (+3)
22% more first-time investments, than exits
New positions opened: 78 | Existing positions closed: 64
15% more call options, than puts
Call options by funds: $211M | Put options by funds: $184M
2% more funds holding
Funds holding: 457 → 464 (+7)
0.96% more ownership
Funds ownership: 91.12% → 92.08% (+0.96%)
1% less repeat investments, than reductions
Existing positions increased: 157 | Existing positions reduced: 158
1% less capital invested
Capital invested by funds: $10.8B → $10.7B (-$152M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$299M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$137M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$94.4M |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$52.5M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$34.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$94.1M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$80.6M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$66.5M |
| 4 |
Man Group
London,
United Kingdom
|
-$38.9M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$37.8M |
SRPT Hedge Fund Activity: Q4 2024 in Review
464 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q4 2024, worth a combined $10.7B — down 1.4% from $10.8B a quarter earlier.
Buyers outnumbered sellers: 78 funds opened new SRPT positions and 64 closed out — a net gain of 14 holders — while 157 added to existing stakes and 158 trimmed.
The largest buyer was Capital International Investors, adding an estimated $299M. The largest seller was Jacobs Levy Equity Management, exiting entirely with an estimated $94.1M sold.
- 464 institutional investors held Sarepta Therapeutics (SRPT) as of Q4 2024, up from 457 in Q3 2024.
- Funds reported $10.7B of Sarepta Therapeutics stock for Q4 2024, down 1.4% quarter-over-quarter.
- 78 funds opened new Sarepta Therapeutics positions in Q4 2024 and 64 closed out, a net change of +14 holders.
- The largest Sarepta Therapeutics buyer in Q4 2024 was Capital International Investors, an estimated $299M added.
- The largest Sarepta Therapeutics seller in Q4 2024 was Jacobs Levy Equity Management, an estimated $94.1M sold.
Based on aggregated 13F filings for Q4 2024.